8-K: Terns Pharma Secures Global TERN-701 Rights

Terns Pharmaceuticals amended its agreement with Hansoh, gaining exclusive worldwide rights to TERN-701 outside the Hansoh Territory for a $1 million upfront fee and tiered royalties.

Summary

• Terns Pharmaceuticals, Inc. (the Company) and its subsidiaries entered into an Amendment to its Exclusive Option and License Agreement with Hansoh (Shanghai) Healthtech Co., Ltd. and its affiliates (Hansoh) on January 16, 2026.
• The original agreement, dated July 27, 2020, granted Hansoh an exclusive license for TERN-701 in oncology within mainland China, Taiwan, Hong Kong, and Macau (the Hansoh Territory).
• Under the Amendment, Hansoh granted Terns an exclusive, royalty-bearing, sublicensable, perpetual, and worldwide (excluding the Hansoh Territory) license for therapeutic products containing TERN-701 as the sole active ingredient (701 Products).
• This new license covers certain patents and patent applications (Exclusively Licensed Hansoh Patents) invented by Hansoh during its activities under the original agreement.
• This exclusive license replaces a previous non-exclusive, non-sublicensable, royalty-free, fully paid license to the Exclusively Licensed Hansoh Patents that Hansoh had granted to CaspianTern, LLC, a Terns subsidiary.
• Terns is obligated to pay Hansoh a one-time upfront license fee of $1.0 million.
• Terns will also pay tiered royalties ranging from 0.75% to 1.25% on annual net sales of 701 Products in Terns' territory, where sales are covered by a valid claim of an Exclusively Licensed Hansoh Patent, subject to specified reductions.

Sentiment

Score: 8

Explanation: The acquisition of exclusive worldwide rights for a key therapeutic asset like TERN-701 is a significant positive strategic development for a pharmaceutical company, enhancing its long-term commercial potential despite the associated upfront and royalty costs.

Positives

• Terns Pharmaceuticals gained exclusive, worldwide rights (excluding the Hansoh Territory) to develop, manufacture, and commercialize therapeutic products containing TERN-701.
• The new exclusive license replaces a less favorable non-exclusive, non-sublicensable, royalty-free, fully paid license, significantly strengthening Terns' intellectual property and commercial position for TERN-701.

Negatives

• Terns Pharmaceuticals is obligated to pay a one-time upfront license fee of $1.0 million to Hansoh.
• Terns will incur ongoing tiered royalty payments ranging from 0.75% to 1.25% on annual net sales of 701 Products in its territory.

Future Outlook

Terns Pharmaceuticals now holds exclusive worldwide rights (excluding the Hansoh Territory) to research, develop, manufacture, use, distribute, sell, and otherwise exploit therapeutic products containing TERN-701 as the sole active ingredient. This expanded license is expected to facilitate broader global development and commercialization efforts for TERN-701.

Industry Context

This amendment reflects a common strategic maneuver in the pharmaceutical industry where companies adjust licensing agreements to optimize the development and commercialization pathways for drug candidates. By securing exclusive worldwide rights for TERN-701, Terns Pharmaceuticals aims to consolidate control over a key oncology asset, potentially enhancing its competitive position and market reach in a highly competitive therapeutic area.

Stakeholder Impact

• Shareholders: Potential for increased long-term value due to expanded market access and control over a key oncology asset, TERN-701.
• Customers/Patients: Potential for broader availability of TERN-701 globally if development and commercialization are successful.

Next Steps

• The Company intends to file the Amendment as an exhibit to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.
• Terns Pharmaceuticals will proceed with the research, development, manufacturing, use, distribution, sale, and exploitation of 701 Products in its newly expanded exclusive territory.

Key Dates

Recommendation

The securing of exclusive worldwide rights for TERN-701 outside the Hansoh Territory represents a significant strategic enhancement for Terns Pharmaceuticals, expanding the potential market for a key oncology asset. While the agreement involves an upfront payment and future royalties, the transition from a non-exclusive to an exclusive license for Hansoh-invented patents strengthens Terns' intellectual property position and commercial prospects. This development is fundamentally positive for long-term value creation, warranting a 'buy' recommendation for investors with a long-term horizon, pending further clinical and commercial progress.

Keywords

Terns Pharmaceuticals, TERN-701, Hansoh, license agreement, oncology, intellectual property, pharmaceutical, drug development, exclusive rights